Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: J Biomol Screen. 2011 Aug 5;17(2):237–244. doi: 10.1177/1087057111414903

Fig. 3.

Fig. 3

Use of the scintillation proximity assay (SPA) for type I protein arginine methyltransferase (PRMT1) inhibitor characterization. (A) Concentration-dependent inhibition of PRMT1 activity by S-adenosyl-L-homocysteine (SAH). (B) Concentration-dependent inhibition of PRMT1 activity by NS-1. (C) Effect of DMSO on PRMT1 activity. Each reaction mixture contained 0.9 μM 3H-SAM, 37 nM PRMT1, and 2.5 μM H4-BTN. Then, 20 mg/mL of beads was added after the reaction.